No Data
Asymchem Laboratories Proposes New Share Incentive Schemes
Asymchem Laboratories (06821) intends to grant 5.216 million shares of A-shares restricted stock.
Asymchem Laboratories (06821) announced that the company plans to launch a restricted stock incentive plan for A shares in 2025. This plan...
Retail Investors Are Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥2.0b Last Week
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.
WuXi AppTec leads the surge of Hong Kong stock pharmaceutical shares, while Global Biomedical investment and financing shows signs of recovery.
① The WuXi AppTec system leads the rise of Hong Kong pharmaceutical stocks, which Bullish factors are worth paying attention to? ② Global Biomedical investment and financing has seen some recovery, how do Institutions view it?
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) Stock Catapults 26% Though Its Price And Business Still Lag The Market
